OnTimeBio LTD

Dor Yuval , HUJI, School of Medicine - IMRIC, Developmental Biology and Cancer Research
SHEMER Ruth, HUJI, School of Medicine - IMRIC
Glaser Benjamin

Company Profile

OnTimeBio is a cross-indication liquid biopsy (blood test) used to identify disease before symptoms appear. It is valid for cancer, neurological, metabolic, autoimmune, inflammatory and cardiovascular diseases

A liquid biopsy is a non-invasive alternative to surgical biopsies.  Using a simple blood test, doctors can discover traces of DNA to confirm a diagnosis or to monitor treatment.  Liquid biopsy technology is already FDA-approved for the identification of non-small cell lung cancer, however the technology has been limited to the identification and treatment of cancer, prenatal testing and to the monitoring organ transplants.

OnTimeBio has developed a liquid biopsy platform technology for a wider range of indications.  Our blood test detects many diseases before clinical symptoms appear, and enables more precise and less expensive monitoring of a patient’s response to treatment.

OnTimeBio's platform is applicable to multiple disease areas including: cancer, the central nervous system, heart, liver and pancreatic diseases such as diabetes, as  well as other diseases such as NASH, MS, Sepsis, as well as Alzheimer’s and more. This innovative, minimally invasive blood test is set to replace traditional biopsies for any disease. 

Contact for more information:

Mel Larrosa
VP Business Development Healthcare